Promising breast cancer treatment

Source: Agencies | June 1, 2009, Monday |

Print Edition

DRUGS targeting an enzyme known as PARP show promise as treatments for some of the most aggressive and difficult-to-treat forms of breast cancer, according to new research.

The findings were presented yesterday at the annual meeting of the American Society of Clinical Oncology.

Mid-stage results from a PARP inhibitor developed by BiPar Sciences Inc show that it improved survival by 60 percent compared with chemotherapy alone for women with "triple negative breast cancer."

And a small trial of AstraZeneca Plc's olaparib in women with advanced breast cancer linked to genetic mutations showed that it shrank tumors in a third of patients.

PARP is short for "poly (ADP-ribose) polymerase," which is used by cancer cells to repair DNA damage, including the damage inflicted by chemotherapy drugs.

Dr Barry Sherman, head of development at BiPar, presented the results from a 116-patient trial of its intravenous PARP inhibitor, known as BSI-201, which is being studied in women with "triple negative" metastatic breast cancer, a very aggressive form of the disease that has no other treatment beyond chemotherapy.

World

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Promising breast cancer treatment

Email this to your friend